✦ LIBER ✦

APOPROTEIN B: A MARKER OF ATHEROGENIC DYSLIPIDEMIA

✍ Scribed by António, N.; Lourenço, C.; Monteiro, S.; Costa, S.; Monteiro, P.; Gonçalves, F.; Gonçalves, L.; Freitas, M.; Providência, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of fenofibrate on atherogenic dy

✍ Michael H. Davidson; Harold E. Bays; Evan Stein; Kevin C. Maki; Robert A. Shalwi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

CETP, a key player in atherogenic dyslip

✍ John M. Chapman; Maryse Guerin 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 97 KB

The therapeutic modulation of atherogeni

✍ Manfredi Rizzo; Ali A. Rizvi; Giovam Battista Rini; Kaspar Berneis 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 333 KB

Effects of the PPAR-δ agonist MBX-8025 o

✍ Yun-Jung Choi; Brian K. Roberts; Xueyan Wang; J. Casey Geaney; Sue Naim; Kathlee 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 464 KB

Pharmacological modulation of cholestery

✍ Wilfried Le Goff; Maryse Guerin; M.John Chapman 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 630 KB

The predictive role of atherogenic dysli

✍ Kaspar Berneis; Manfredi Rizzo; Giatgen A. Spinas; Gabriele Di Lorenzo; Gaetana 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 206 KB